44.200.30.73
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup

Combination of OPT-302 and aflibercept shows promise in persistent DME

Posted on July 26, 2020

The addition of a VEGF-C/-D inhibitor (OPT-302) to treatment with an anti-VEGF-A monotherapy is well tolerated and improves visual outcomes in patients with persistent diabetic macula edema, according to a presentation at the 2020 ASRS Virtual Meeting.

VEGF-C/-D is thought to contribute to treatment resistance with anti-VEGF-A monotherapy, so dual-targeted inhibition of VEGF-C/-D and VEGF-A could potentially help in the management of persistent diabetic macula edema.

This interim analysis from the Phase 1b dose escalation study, 9 patients with persistent diabetic macula edema with a mean of 6.3 (SD 2.4) injections of prior anti-VEGF-A monotherapy were switched to a combination therapy of OPT-302 and aflibercept. Treatment was well tolerated at 3 different dose levels and no dose limiting toxicities were noted.

At week 12, the mean change in BCVA increased by + 7.7 letters from baseline. BCVA was observed to improve with increasing doses of OPT-302 + aflibercept.

At week 12, central subfield thickness was also reduced by -71µm from baseline and 67% of patients had a ≥ 50% reduction in excess foveal thickness.

Reference
Boyer D et al. Switching to combination OPT-302 with aflibercept from prior Anti-VEGF-A monotherapy in eyes with persistent diabetic macula edema (DME). Presented at: 2020 ASRS Virtual Meeting

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-